Bliss GVS Pharma Share Price
671.30+31.95 (+5.00%)
+323.11% past 1 Year
News
Bliss GVS Pharma informs about open offer
Equity
BLISSGVS
Bliss GVS Pharma rises on securing Inspection Closure Report from WHO
Equity
BLISSGVS
Bliss GVS Pharma gains WHO GMP compliance approval for Palghar facility
Equity
BLISSGVS
Bliss GVS Pharma informs about disclosure
Equity
BLISSGVS
Bliss GVS Pharma Q4 Consolidated Net Profit Rises to Rs 35.50 Crores, Up from Rs 15.50 Crores YoY
Equity
BLISSGVS
Bliss GVS Pharma Reports Q4 Revenue Growth to Rs 257 Crores, Up from Rs 198 Crores YoY
Equity
BLISSGVS
Bliss GVS Pharma Reports Strong Q4 EBITDA Growth to Rs 44.40 Crores, Margin Expands to 17.3%
Equity
BLISSGVS
Bliss GVS Pharma reports Profit after tax of 32.42 Crores, in the March 2026 quarter
Equity
BLISSGVS
Bliss GVS Pharma informs about credit rating
Equity
BLISSGVS
Bliss GVS Pharma informs about trading window closure
Equity
BLISSGVS
Bliss GVS Pharma Addresses Rumors of Acquiring Anupam Rasayan, No Official Decision Yet.
Equity
BLISSGVS
Anupam Rasayan May Acquire Stake in Bliss GVS Pharma as per CNBC Aawaz Report.
Equity
BLISSGVS
Bliss GVS Pharma - Quaterly Results
Equity
BLISSGVS
Bliss GVS Pharma Reports Strong Q3 EBITDA Growth of 16% YoY to Rs 34.80 Crores.
Equity
BLISSGVS
Bliss GVS Pharma Reports Q3 Revenue Growth to Rs 220 Crores, Up from Rs 210 Crores YoY.
Equity
BLISSGVS
Bliss GVS Pharma Q3 FY26 Net Profit Declines YoY to Rs 23.30 Crores
Equity
BLISSGVS
Bliss GVS Pharma reports Profit after tax of 18.61 Crores, in the December 2025 quarter
Equity
BLISSGVS
Bliss GVS Pharma Establishes Wholly Owned Subsidiary in Democratic Republic of Congo
Equity
BLISSGVS
Bliss GVS Pharma’s arm incorporates wholly owned subsidiary in Kenya
Equity
BLISSGVS
Bliss GVS Pharma Establishes Theralife Pharma in Kenya
Equity
BLISSGVS